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ABSTRACT
Introduction: Cost-effectiveness analysis (CEA)
using country-specific thresholds tied to gross
domestic product (GDP) might not be
appropriate in countries with low healthcare
investment and a high disease burden as a
consequence.
Methods: Using data from previously published
CEA of rotavirus vaccination across nine
countries worldwide, we calculated the cost
neutral price (Pn) for the new intervention
that reflects the price resulting in no net
increase in health care costs compared with
the current situation, and the maximum price
(Pm) obtained with an incremental cost-
effectiveness ratio (ICER) at the threshold
value of 1 9 GDP/capita.
Results: In countries with low GDP/capita, the
paradoxical finding for rotavirus vaccination is
that the Pm is much higher than in countries
with a high GDP/capita. On the other hand, the
Pn for the low GDP/capita countries is much
lower than for high GDP/capita countries
because of the low investment in health care.
Conclusion: In countries with low healthcare
investment and a high disease burden, the
difference between the Pn and Pm for
rotavirus vaccine which is the price range
within which the ICER is below the World
Health Organization (WHO) threshold value, is
large. One reason could be that the WHO
threshold value may not properly account for
the local opportunity cost of health care
expenditures. Therefore, either alternative
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threshold values should be selected or
alternative economic assessment tools should
be considered, such as budget optimisation or
return on investment, if we want to
communicate about real economic value of
new vaccines in those countries.
Keywords: Budget optimisation; Cost-
effectiveness analysis; Cost neutral price;
Economic evaluation; Gross domestic product
per capita; Maximum price; Return on
investment; Threshold value; Vaccination
INTRODUCTION
Current economic assessment of a new medical
intervention such as a drug, device, or vaccine
aims to provide local decision makers with
information on the additional benefit
generated for the additional cost incurred,
compared with the existing situation [1, 2].
This is most commonly conducted using cost-
effectiveness analysis (CEA), with results
expressed with incremental cost-effectiveness
ratios (ICERs). The ICER can be used to help
define an acceptable ‘‘value-based’’ price range
for the new intervention, with the maximum
acceptable price being the price at which the
ICER crosses a defined threshold [2]. The gross
domestic product (GDP) per capita is a well-
accepted threshold measure, as proposed and
recommended by the World Health
Organization (WHO) [3, 4]. If the price of the
new technology leads to an ICER below the
threshold, that price is qualified as being highly
cost-effective following the interpretation of the
WHO guidelines [5].
CEA is a well-established economic
assessment technique in healthcare [6–8]. It
was initially developed in industrialized
countries with mature healthcare systems
which had already made considerable
investments in healthcare infrastructure. More
recently, the use of CEA has been extended to
economic evaluations of health interventions in
developing countries. For example, CEA results
for rotavirus vaccination have been reviewed in
developed countries [9] and developing
countries [10]. These two reviews reported that
the vaccine was very cost-effective in low-
income countries, but the picture was mixed
in high-income countries. A similar result was
reported by Rheingans et al. [11] comparing the
cost-effectiveness and price setting of rotavirus
vaccination for different country groups in
Latin America from low income (L), via low
middle (LM), to upper middle income (UM).
They reported that the price per vaccine dose
that is cost-effective was higher in L countries
than in LM and UM countries. This is counter-
intuitive, as it would be expected that the
maximum price for favorable cost-effectiveness
would be lower in L countries, reflecting the
lower income and lower resources available for
healthcare, compared with higher-income
countries. The authors of these papers did not
attempt to explain this paradoxical finding. The
analysis provided here builds on these previous
reports by seeking to explore how these
apparently paradoxical results could arise.
This paper focuses on rotavirus vaccination
as an example. It is an interesting example, as
the rotavirus vaccine has been the subject of
CEA in a range of countries worldwide, and the
benefits obtained from the vaccine appear quite
different in high- versus low-income countries
[12]. In low-income countries, the benefit of
vaccination is primarily a reduction in the high
mortality rate. In high-income countries, in
addition to a reduced need for hospital care the
benefits are more subtle, such as better time
management for working parents [11, 13].
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In this paper, first a theoretical framework
and interpretation of the ‘‘value-based’’ price
range is presented for a new vaccine program. In
the next step, an application in practice for
rotavirus vaccination using published country-
specific data for rotavirus to estimate the ‘‘value-
based’’ price range in nine countries was
conducted. This allowed an analysis of the
relationship of the ‘‘value-based’’ price range
for each country and the GDP/capita. Finally,
the findings are interpreted and
recommendations made for alternative/
additional economic evaluations.
METHODS
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Theoretical Framework
The first step demonstrates, using mathematical
equations, the relationship between the price of
a new intervention, the ICER, the threshold
value for cost-effectiveness, and the cost neutral
price (Pn) and the maximum price (Pm) linked
to that threshold.
The relationship between the ICER and the
price of a new intervention is expressed as a
linear function (y = ax ? b), where y (=ICER) is
the dependent variable and x (=price or cost of
the new intervention) is the independent
variable, here the cost of the vaccine (CostV).
This relationship is now considered within the
context of a static cohort model for modeling
the cost-effectiveness of the intervention of the
rotavirus vaccine [14]. Additional equations and
variables help to specify which exact parameters
define the slope of the line (a) and which the
intercept (b) that is the remaining disease cost
after the impact of the new intervention
divided by the difference in disease outcomes
attributable to the new intervention.
Calculating the association between the price
of the new intervention and the ICER allows
testing the price range over which it is still cost-
effective. This is defined here as the price range
for which the ICER lies below the threshold
value, defined as 1 9 GDP per capita [3]. The
linear function also indicates at what price the
ICER equals zero (because of no difference in
total cost with the intervention compared with
the total cost without the intervention). This is
referred to as the cost neutral price (Pn). The
maximum price (Pm) above which a new
product is no longer cost-effective is defined
by the point where the threshold value
intersects with the increasing linear function
for new interventions that are more effective
but result in higher total costs than with the
current health care program (see Fig. 1).
Now, we further elaborate on the

















T =  1x GDP/capita
Pn Pm0
Fig. 1 Cost neutral (Pn) and maximum price (Pm) of the
vaccine per dose at a threshold T (e.g., $40,000/life-year
gained). a Slope, b intercept, CostV vaccine cost, GDP
gross domestic product, ICER incremental cost-effectiveness
ratio, Pm maximum price, Pn cost neutral price,
T threshold
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described above. In its simplest form, the
relationship between the ICER and the cost
(price) of a new intervention (vaccine) is
defined by the following equations:
CostDV þ CostVð Þ CostDNV
ENV  EV ¼ ICERT
CostV
ENV  EV þ
CostDV  CostDNVð Þ
ENV  EV ¼ ICER
a ¼ 1
ENV  EV
b ¼ CostDV  CostDNVð Þ
ENV  EV
where:
CostDv Remaining disease-related cost with
vaccination
CostV Acquisition cost of the new
intervention (vaccine)
CostDNV Initial disease-related cost in the
absence of vaccination (no vaccine)
ENV Health losses without vaccination
(no vaccine)
EV Remaining health losses (effects)
with vaccination
ICER Incremental cost-effectiveness ratio
T Threshold (here defined as the GDP/
capita)
a Slope of the line
b Intercept
From the equations above, the slope (a) is
defined by the inverse of the effect difference,
while the intercept (b) is defined by the cost
difference without including CostV divided by
the effect difference.
There is one additional variable to be defined
in the equations, the vaccine impact on disease-
related costs and negative health outcomes:
CostDV ¼ CostDNV  1 VaccineEffectCð Þ
EV ¼ ENV  1 VaccineEffectEð Þ
where:
• VaccineEffectC and VaccineEffectE: the
vaccine effects on costs and negative
outcomes (range of values between 0 and 1)
obtained from randomized clinical trials
entered into the model. For simplicity only
two factors are assessed here, disease-specific
mortality (negative outcomes) and
hospitalization (costs). The output of EV
and ENV is expressed in survival loss
expressed in life-years, in which the
difference between the two is presented as
a gain in survival time.
The vaccine may have different effects on
costs and health outcomes in different elements
of the disease burden. For example, the effect of
the vaccine in reducing hospitalizations,
medical visits or total numbers of cases may
vary, and the effect on the total cost will depend
on the frequency of each of these elements in
the total cost burden. To simplify the model, in
the present paper only one cost component is
considered, hospitalization. In rotavirus disease,
it is normally assumed that deaths occur in
hospitalized cases. Thus, in this simplified case
that reflects an environment with a well-
established health care system, the effects of
the vaccine on costs (hospitalizations) and
health outcomes (deaths) are likely to be equi-
proportionate. It may be different in those
situations where the health care system is less
well developed.
Hypothetical Baseline Model
To illustrate this theoretical framework a model
was constructed for a hypothetically developed
country with a threshold value of $40,000/life-
year gained, equivalent to the GDP per capita of
the hypothetical country. The currency was
selected as $ because international data are
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commonly expressed in $. The model
development is based on experience obtained
from rotavirus disease and the impact of
pediatric rotavirus vaccination in Europe. The
model assumes vaccine coverage of 100%, but
the coverage rate has no impact on the ICER as
long as a static epidemic model is used, because
the coverage rate affects both sides of the ratio
(higher coverage results in both higher costs
and higher effect). Table 1 summarizes the
input values selected.
The baseline value for CostDNV was $60/
subject, calculated from data in studies in a
recent literature review [9]. It represents the
average cost for rotavirus hospitalization in
Europe per child in the birth cohort (i.e., the
total cost of rotavirus hospitalizations averaged
across all children in the cohort). As only a
small percentage of children in the birth cohort
will be hospitalized for rotavirus, the cost per
subject is much smaller than the cost per
hospitalized case or per hospitalization event.
The baseline value for ENV (0.00031/subject) is
based on the following reasoning. The
maximum individual loss in health outcome is
the loss of full life expectancy at birth (78 years,
discounted at 3% per year = 31 years). That
value is multiplied by the disease-specific
mortality rate (0.00001 per year) for infants in
the region to estimate the individual loss in
health outcomes per unvaccinated subject in
the infant population. The perspective is that of
the healthcare system.
Figure 2 shows how the vaccine price range
(Pm–Pn) can shift and change for countries with
different cost-effectiveness thresholds but also
Table 1 Variables, formulae, input values, and output results to calculate the ICER, the cost neutral price (Pn), and the
maximum price of a new intervention (Pm) using a hypothetical model
Variable Formula Input Output
CostDNV $60
CostDv CostDNV 9 (1 - VaccineEffect) $6
CostV at Pn CostDNV - CostDv $54
ENV 0.00031
EV ENV 9 (1 - VaccineEffect) 0.000031




a 1/(ENV - EV) 3,584.23
b (CostDv - CostDNV)/(ENV - EV) –193,548.39
y a 9 Pn ? b $0
Threshold value $40,000/E
Maximum price/course (Pm) (40,000 - b)/(a) $65.16
a slope of the linear regression, b intercept, CostDNV initial disease-related cost in the absence of vaccination (no vaccine),
CostDv remaining disease-related cost with vaccination, CostV vaccine cost; E effect unit (life-year gained), ENV health losses
without vaccination (no vaccine), EV remaining health losses (effects) with vaccination, ICER incremental cost-effectiveness
ratio, Pm maximum price, Pn cost neutral price
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different potential gains in health outcomes
resulting in a change of the slope. As the
threshold value increases, Pm becomes larger.
In addition, as the absolute effect difference
becomes smaller because of a smaller disease
burden in the absence of vaccination (ENV) the
slope of the line steepens. As the amount of
current spend on the disease increases, Pn
becomes larger. Such a situation would be
expected in a high-income country (indicated
by the high GDP per capita threshold value),
with a low disease burden (indicated by the
steeper slope) and a higher current expenditure
on the disease (Pn and Pm both shifted to the
right). Thus, the slope of the line is likely to be
steeper and the absolute difference between Pn
and Pm is lower for countries with a higher
GDP/capita associated with a lower disease
burden and higher disease expenditures in the
absence of vaccination (see Fig. 2).
Country-Specific Data
The next step is to apply this theoretical
approach to real-life published data from nine
countries across the world for which the cost-
effectiveness of rotavirus vaccine has been
evaluated using a similar model [15], taking
the country-specific GDP per capita as the
threshold value. The model adjusts for
different current disease-related costs and
different vaccine impacts in high-income and
low-income countries, and for other factors
related to country-specific conditions such as
life expectancy, unit cost (expressed in $),
disease management, and GDP, among others.
Effects are consistently discounted at 3% per
year. The same current intervention CostDNV
(hospitalization) and ENV (disease-specific
mortality) variables are used as in the base
case model. Cost variables were not discounted
because of the short period (the first 2–3 years)
when health care expenditure on vaccination
and disease-related cost occurs.
RESULTS
Hypothetical Baseline Model
Table 1 shows the results of the base case model.
The two critical points of the vaccine price,
Pn and Pm, related to the ICER and the
threshold value are shown in Fig. 1. The cost
neutral point (Pn = $54) and the maximum
price point (Pm = $65.16) define the price range
over which the vaccine could still be cost-
effective with the threshold set at $40,000 per
life-year gained.
Country-Specific Data
For each country, country-specific values for the
















Fig. 2 Cost neutral (Pn) and maximum price (Pm) at
different thresholds and slope lines. The green line
indicates a country with a low threshold (T3), the red
line a country with an intermediate threshold (T2), and
the blue line a country with a high threshold (T1). As the
threshold increases the cost neutral point (where the line
intercepts the x-axis) shifts to the right and the slope
steepens, reﬂecting higher healthcare expenditure and
lower remaining disease burden. CostV vaccine cost, ICER
incremental cost-effectiveness ratio, PnHC cost neutral price
in high-income country, PnLC cost neutral price in low-
income country, PnMC cost neutral price in middle-income
country, T threshold
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health outcomes (ENV) were used to calculate
the Pn and Pm of the vaccine at the country-
specific threshold (GDP per capita). This
exercise provides a better understanding of the
meaning of a cost-effectiveness result for
countries with different income levels,
expressed through their GDP values. Table 2
presents the input data for each country,
obtained from published sources as follows:
Vietnam [16], Egypt [17], Philippines [18],
Algeria [19], Turkey [20], Portugal [21], France
[15], The Netherlands [22], and Norway [23].
Life expectancy data for all countries were
obtained from WHO Health Statistics 2013
[24], and GDP per capita from World Bank
data [5]. Table 2 also shows the CostDNV and
ENV per subject with the calculated Pn and Pm
at the GDP threshold for each country.
Figure 3 presents the relationship between
Pm and GDP per capita across the nine
countries, plotted from the data in Table 2. It
shows that the countries fall into two groups for
the relationship between Pm and the country-
specific GDP threshold values. For the cluster of
countries with a GDP per capita [$10,000, the
lower the GDP threshold, the lower the Pm. In
this group of countries, the slope is steep, with a
fairly narrow range between Pn and Pm (see
Table 2).
Figure 4 shows an example that illustrates
how the Pm will vary according to the cost-
effectiveness threshold value with a similar
disease burden in the absence of vaccination.
The difference between Norway (GDP per capita
$53,396) and Portugal (GDP per capita $23,363)
illustrates that effect on Pm with a higher
threshold. The Pm with one rotavirus death
per year is $28.56 in Norway, considerably
higher than the maximum price of $14.04 in
Portugal (left hand of the three lines for
Portugal in the figure [dash-dotted line]). The
three lines for Portugal illustrate the effect of
increasing the disease burden in the absence of
vaccination from one rotavirus death per year
(left-hand [dash-dotted] line) to two rotavirus
deaths per year (middle [dashed] line) and then
to three rotavirus deaths per year (right-hand
[dashed] line), while assuming expenditure for
the disease treatment remains constant. It can
be seen that as the disease burden (number of
rotavirus deaths per year) increases, as expected
Pm also increases even without a change in the
threshold. This is because as the disease burden
at baseline increases with the increasing
number of deaths, the benefit of the vaccine
in reducing the disease burden will also be
higher in absolute value, the slope of the line in
Fig. 4 will be lower and therefore the price range
over which the vaccine is cost-effective will be
larger. The vaccine price range for cost-
effectiveness (Pm–Pn) is, however, much larger
in Norway than in Portugal, despite a disease
burden that is 1.3 times lower in Norway than
Portugal.
In the second cluster of countries, those
with a low GDP per capita, the pattern of
systematic decline of the Pm with lower GDP
per capita no longer fits the data. The baseline
disease-related healthcare costs are so low
(CostDNV), and the remaining health burden
(ENV) so high that the slope factor ‘a’ is also




The slope angle is very shallow because of
the high reduction in losses in health outcomes,
and the Pn value is close to zero because of the
low current expenditure per case for the disease
and thus the potential for only minimal cost
offsets.
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DISCUSSION
An important outcome from the analyses
presented in this paper is that the results for
rotavirus vaccination split the countries into
two clusters with different characteristics using
the GDP per capita as a measure of distinction.
Countries with a High GDP/Capita
CEA has been applied mainly in higher-income
countries for many years now as a technique
currently used to compare the value of
alternative treatments and/or in combination
with threshold values representing willingness
to pay for an incremental unit of health as the
basis for ‘‘value-based’’ pricing. It is an
established method in health economic
assessment to help to define the price at which
a new intervention is considered good value for
money compared with the current standard of
care at the individual, most often, patient level
[25, 26].
Typically, a new intervention has an impact
on both the cost and the effect side in the ICER.
CEA makes most sense in capturing the value of
a new intervention when there is investment in
healthcare for the disease of interest but with
disease burden still remaining. Under such
circumstances a new intervention can achieve
both an important cost offset and a reasonable
effect gain. It is then meaningful to estimate a
cost per life-year or quality-adjusted life-year
gained in relation to a pre-specified threshold
within a price range. Such situations are likely
to occur within mature healthcare markets.
ICER values calculated from CEA can be useful
in defining the acceptable price range in such
countries. The steeper the line in Fig. 1, the
narrower the price band over which the ICER
moves from Pn to Pm. When Pn equals Pm, the
focus of price setting may shift from cost-
effectiveness to cost savings.
The maximum price in this group of countries
is strongly influenced by the threshold value
(GDP per capita) and the remaining disease
burden in the absence of vaccination. As the
threshold value increases, the maximum price
also increases. In addition, as the disease burden
in the absence of vaccination increases, the slope
of the line decreases and the maximum price
increases even without a change in the threshold,
as illustrated in the present analysis using



























Fig. 3 Relationships between baseline values of Pm and
GDP by country. Countries with low GDP per capita
(squares): A Algeria, E Egypt, Ph Philippines, V Vietnam.
Countries with high GDP per capita (diamonds): F France,
N Norway, NL Netherlands, P Portugal, T Turkey. GDP




















Fig. 4 Effect on the maximum price (Pm) of increasing
the threshold (GDP in Norway compared with Portugal)
and increasing the disease burden (number of rotavirus
deaths per year in Portugal increased from P1 to P2 to P3).
CostV Vaccine cost, GDP gross domestic product, ICER
incremental cost-effectiveness ratio, Pm maximum price,
TN threshold for Norway, TP threshold for Portugal
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Countries with Low GDP/Capita
The situation is quite different when
conducting CEA outside mature healthcare
markets. This reflects an environment with
low existing healthcare investment (CostDNV)
and high disease burden (ENV) as a
consequence. The low existing healthcare
expenditure on the disease allows minimal
scope for cost offsets, so the Pn is close to
zero. The high disease burden has the potential
for large reductions in health outcome losses, so
an effective intervention can be cost-effective
(as defined by the GDP per capita threshold)
over a wide price range, because of the low
slope.
This wide price range within which rotavirus
vaccination is cost-effective offers a possible
explanation for the paradoxical results for
rotavirus vaccination CEA reported in the
literature. Reviews of rotavirus vaccination
reported high cost-effectiveness in low-income
countries and a mixed picture in high-income
countries [10]. A study in Latin America found
that the vaccine price that was apparently cost-
effective was higher in low-income countries
than in middle-income countries [11]. Yet, it is
clear that high prices are not affordable or
acceptable for low-income countries. The
present analysis suggests that the apparently
better cost-effectiveness results at a relatively
high intervention price in countries with low
GDP per capita reflects the large increases
in health outcomes possible in such
environments.
In situations with high potential increases in
health outcomes accompanied by low current
health care expenditures, ICER values
calculated by conventional CEA have limited
value in defining a reasonable price band for a
new intervention. Even if the estimated ICER
value indicates that a high price would be cost-
effective based on a 1 9 GDP threshold, the
price may be rejected on the basis of the
affordability of the acquisition cost [27]. A
price close to the Pn is likely to be preferred
by the low-income country, but as the Pn is
likely to be very low (because low existing
healthcare expenditure offers minimal scope
for cost offsets), such a price might not be seen
as reasonable by the seller of the new
intervention. Thus, if Pn and Pm define price
bands in low-income countries that are
questionable at the extremes for both payers
and producers, CEA performed under these
conditions might not be able to serve the
same function in low-income countries as in
high-income countries, where CEA is used to
help define a reasonable price band.
Although the value of $10,000 GDP per
capita that differentiates the two groups of
countries in this analysis is an arbitrary
threshold, it acts as a proxy for the degree of
healthcare development in a country. Countries
in the group with a high GDP per capita
typically have well-established healthcare
systems with infrastructure already in place. In
these countries, the fixed cost of healthcare
infrastructure is already accounted for and
variable costs for treatment are well accepted.
In these cases, decisions about new
interventions can be made at the margin using
incremental costs and benefits for individuals,
as described in the ICER calculated by
conventional CEA that assumes that prices are
a fair representation of opportunity costs.
Conversely, in the countries with a low GDP
per capita, healthcare infrastructure may be
limited and the healthcare system not yet fully
developed. Because of this, prices defined as
acquisition costs may not reflect the true
opportunity cost of the intervention. In these
situations, affordability and practical
considerations such as the alternative possible
1104 Adv Ther (2014) 31:1095–1108
uses for the additional healthcare investment
(including other health investments or
non-health investments) are important
considerations.
Potential Future Directions
Our results suggest that CEA is not necessarily
the optimum economic analysis method for
defining a feasible price band for a new
intervention in low-income countries [28].
Measuring shadow prices could be an
alternative if cost-benefit analysis or CEA is
used for economic assessment of new
interventions in those situations [29]. In low-
income environments with low health
investment and a high disease burden, almost
any improvement in health will require extra
spending. The question therefore should be
phrased not as a comparison of the new
intervention with the existing situation which
could be considered as a substitution economy,
but as a consideration of which alternative
interventions would provide the greatest
additional health benefit for a given amount
of extra money spent—an add-on economy
instead of substitution [30].
Health problems that affect a whole
population (as is often the case in low-income
countries) should be assessed using economic
approaches, tools or techniques that describe
the problem well at the population level. In
addition, the impact of increased spending on
health care on other sectors of the economy
should be included in the analyses.
Budget optimization modeling (BOM) [31]
and return on investment (ROI) [17] are possible
alternative economic techniques for estimating
the true value of a new intervention in low-
income countries. The choice of technique
should be driven by the economic question
asked, a good understanding of the economic
problem to be solved, data availability, and the
requirements of the decision makers who need
to understand and use the economic analysis.
BOM is attractive when the problem is one of
integrating different management options into
a specific health goal within certain constraints,
such as budgets and/or logistics [32]. Its
application is not especially complicated.
Furthermore, the BOM is well suited to the
type of problem that needs to be addressed in
low healthcare investment areas. Instead of
comparing a new intervention with the
existing situation, which as described here has
weaknesses when applied to countries with a
low GDP/capita, it considers the question of
how best to optimize the use of the health
investment budget available today. It is
essentially a more flexible and dynamic
version of budget impact assessment. However,
a limitation of budget optimisation is that it is
more difficult to evaluate the effects of
uncertainty than in conventional CEA,
because the effects of varying the proportions
of different interventions in the mix have to be
taken into account, as well as uncertainty in the
parameters describing each intervention.
ROI analysis is also attractive. It is based on
the premise that the health problem must be
substantial at population level and compares
different investment policies in terms of benefit
within that population projected over time as a
function of tax payment/income for the
government. It can compare investment in
prevention through vaccination with either
doing nothing or increasing healthcare
infrastructure to reach the same health benefit
level. However, a limitation is that it considers
health benefits only in terms of the effects on
future tax revenues, and does not take into
account intangible benefits such as the
improvement in human welfare arising from
reductions in the disease burden.
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A further area of uncertainty is whether the
average GDP per capita reflects the right
threshold value [33]. First, the distribution of
GDP per capita in low-income countries is often
skewed, and much of the population may
receive little benefit from any healthcare
services offered because they do not have
access to them. This issue is not reflected in
the average per-capita GDP value, but is
reflected in the remaining health problem
(ENV). For example, Egypt has a relatively high
GDP per capita, close to the value reported for
Algeria, while the disease burden (ENV) is high
and comparable with populations such as the
Philippines (see Table 2). Second, GDP per
capita does not necessarily relate to the
investment a country is willing to make in
healthcare, which may be affected by other
competing priorities.
The present analysis has limitations. Not all
the different costs and benefits related to
rotavirus vaccination have been included in
the analysis, as the focus was only on the
parameters that drive the main results,
hospitalization and mortality. However, a
more detailed assessment is not likely to
change the main discrepancy between the
clusters of countries with high versus low
income. Furthermore, the analysis has only
investigated a single intervention and disease,
rotavirus vaccination. The next step would be to
explore whether other disease areas show
similar patterns, which would indicate
whether the findings are likely to be
generalizable.
CONCLUSION
The paradoxical results of CEA in countries with
low GDP per capita described in this paper
suggest that conventional CEA may have
limited applicability for defining an acceptable
price range in such situations. This may be
because current methods for cost-effectiveness
analyses do not properly account for the
opportunity costs of the new intervention in
low-income countries. Alternative economic
methods may be better suited to the economic
assessment of healthcare interventions in low-
income countries, and this should be explored
in greater detail.
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